A1 Refereed original research article in a scientific journal
Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetes
Authors: Aidan McGlinchey, Tim Sinioja, Santosh Lamichhane, Partho Sen, Johanna Bodin, Heli Siljander, Alex M Dickens, Dawei Geng, Cecilia Carlsson, Daniel Duberg, Jorma Ilonen, Suvi M Virtanen, Hubert Dirven, Hanne F Bentsen, Karin Zimmer, Unni C Nygaard, Matej Oresic, Mikael Knip, Tuulia Hyotylainen
Publisher: Elsevier
Publication year: 2020
Journal: Environment International
Journal acronym: Environment International
Article number: 105935
Volume: 143
DOI: https://doi.org/10.1016/j.envint.2020.105935
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/48047769
In the last decade, increasing incidence of type 1 diabetes (T1D) stabilized in Finland, a phenomenon that coincides with tighter regulation of perfluoroalkyl substances (PFAS). Here, we quantified PFAS to examine their effects, during pregnancy, on lipid and immune-related markers of T1D risk in children. In a mother-infant cohort (264 dyads), high PFAS exposure during pregnancy associated with decreased cord serum phospholipids and progression to T1D-associated islet autoantibodies in the offspring. This PFAS-lipid association appears exacerbated by increased human leukocyte antigen-conferred risk of T1D in infants. Exposure to a single PFAS compound or a mixture of organic pollutants in non-obese diabetic mice resulted in a lipid profile characterized by a similar decrease in phospholipids, a marked increase of lithocholic acid, and accelerated insulitis. Our findings suggest that PFAS exposure during pregnancy contributes to risk and pathogenesis of T1D in offspring.
Downloadable publication This is an electronic reprint of the original article. |  |
